Champions Oncology Inc. (CSBR)
| Bid | 5.97 |
| Market Cap | 88.91M |
| Revenue (ttm) | 42.88M |
| Net Income (ttm) | 2.92M |
| EPS (ttm) | 0.21 |
| PE Ratio (ttm) | 30.71 |
| Forward PE | 42.6 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 6.83 |
| Volume | 14,099 |
| Avg. Volume (20D) | 34,260 |
| Open | 6.31 |
| Previous Close | 6.39 |
| Day's Range | 6.26 - 6.45 |
| 52-Week Range | 3.75 - 11.99 |
| Beta | 0.55 |
| Ex-Dividend Date | n/a |
About CSBR
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for CSBR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAnalysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · accessnewswire.com
CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 MillionThis release contains a headline correction from the previous publication. Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15...
3 weeks ago · accessnewswire.com
Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025HACKENSACK, NJ / ACCESS Newswire / September 10, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, ...
2 months ago · accessnewswire.com
Champions Oncology Reports Record Annual Revenue of $57 MillionTotal annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced it...
